GlassScriptPhysician profile
Robert Wh Rampton
NPI 1376925842
$6,830.93
in general payments reported to CMS, 2019-2025
24 companies · $3,355 in 2025
The $3,355 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2021: $92.75 · 2022: $303 · 2023: $780 · 2024: $2,065 · 2025: $3,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,930 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,930.25 |
| Education | $270.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,437.17 | 2019-2025 | Dupixent, Libtayo |
| Abbvie INC. | $832.57 | 2019-2025 | |
| Janssen Biotech, INC. | $782.42 | 2023-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $563.05 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $408.16 | 2021-2025 | Blu-U, Ilumya |
| Novartis Pharmaceuticals Corporation | $382.18 | 2024-2025 | |
| Leo Pharma INC. | $357.94 | 2024-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $320.27 | 2024-2025 | Ebglyss, Olumiant, Taltz |
| Ucb, INC. | $319.73 | 2023-2025 | Bimzelx |
| Incyte Corporation | $268.96 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $184.53 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $158.50 | 2023-2025 | Zoryve |
| Amgen INC. | $135.22 | 2024-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $130.23 | 2024-2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $112.22 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $85.66 | 2023-2024 | Vtama |
| Botanix Sb INC | $69.93 | 2025 | Sofdra |
| Revance Therapeutics, INC. | $67.78 | 2025 | Daxxify |
| Organon LLC | $65.18 | 2025 | Vtama, Nexplanon |
| Genzyme Corporation | $40.97 | 2024 | |
| Verrica Pharmaceuticals INC. | $36.55 | 2023-2024 | Ycanth |
| Almirall LLC | $35.54 | 2025 | Seysara |
| Lnhc, INC | $18.43 | 2025 | Zelsuvmi |
| Celltrion USA INC. | $17.74 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rampton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.